2nd ADC Process Development Summit

Memo

With cutting-edge strategies and industry insights, the 2nd ADC Process Development Summit is back with a mission to boost conjugation yield, optimize purification, and streamline production to meet regulatory standards all whilst minimizing costs and timelines. Join AstraZeneca, Bristol Myers Squibb, Pfizer and a community of industry experts in process development, conjugation, purification, control, CMC, and engineering. With a focused discussion on process development challenges, innovative solutions and practical takeaways, leave equipped with the technical knowledge and connections to revolutionize your ADC manufacturing process. This Summit is a must attend for everyone looking to increase conjugation yield and enhance TFF, implement rigorous control strategies for superior drug substance quality, develop scalable processes to cut unit operations, accelerate production timelines, and navigate regulatory landscapes with ease. Don’t miss this Summit, where innovation meets implementation, ensuring your ADC process development reaches its optimal efficacy and efficiency!     URLs:Brochure: https://go.evvnt.com/2471245-0?pid=5569 Tickets: https://go.evvnt.com/2471245-2?pid=5569  Date and Time: On Tue, 17 Sep 2024 08:00 - Thu, 19 Sep 2024 16:45 Venue details: The Westin Boston Seaport District, 425 Summer Street, Boston, Massachusetts, 02210, United States Prices:Drug Developer Conference + Workshop Day Ticket: USD 4097.00,Drug Developer Conference Only: USD 2899.00,Solution Provider Conference + Workshop Day: USD 4997.00,Solution Provider Conference Only: USD 3599.00 Speakers: Benjamin Hutchins, Vice President, Technical Operations, Mythic Therapeutics, Brandon Coyle, Senior Research Scientist II, Gilead Sciences, Cuihua (Tracy) Zhu, Associate Director, Pheon Therapeutics Ltd, Dharti Kothari, Senior Scientist - Downstream Process Development, Independent, Engin Ayturk, Senior Director, CMC Bioconjugation, Process Development and Manufacturing, Exelixis Inc., Eric Lacoste, Head of ADC Conjugation Development/Global CMC Development, Sanofi, Hong Shen, Principal Scientist, Johnson and Johnson Services, Inc, Hui Wei, Director - Chair, Biologics Specification Committee, Analytical Chemistry Manufacturing and Controls Strategy Lead, Bristol Myers Squibb, Jianxin Guo, Director - Regulatory Chemistry Manufacturing and Controls Biotechnology, Eli Lilly and Co., Joshua Hunter Director - Conjugation Process Development, Pfizer, Linan Ha, Director, Regulatory Affairs, CMC, AstraZeneca, Nimish Gupta, Senior Staff Engineer, Regeneron Pharmaceuticals Inc, Prakash Manikwar, Assocaite Director, AstraZeneca, Robert Hughes, Senior Director - Pharmaceutical Sciences, Cidara Therapeutics Inc., Sarah Owen, Senior Scientist, Seagen, Shiyue Zhou, Principal Research Scientist I, Abbvie, Vineet Kumar, Senior Director - Development, DP manufacturing and Chemistry, Manufacturing, and Controls Project Management, Exelixis Inc.